CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
Stocks News & Analysis
stocks
AMD earnings: Data center demand still looks quite strong to us
stocks
PayPal earnings: Growth slows, new CEO appointed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,175.50 | 5.40 | -0.06% |
| CAC 40 | 8,262.16 | 82.66 | 1.01% |
| DAX 40 | 24,603.04 | 177.75 | -0.72% |
| Dow JONES (US) | 49,501.30 | 260.31 | 0.53% |
| FTSE 100 | 10,402.34 | 87.75 | 0.85% |
| HKSE | 26,847.32 | 12.55 | 0.05% |
| NASDAQ | 22,904.58 | 350.61 | -1.51% |
| Nikkei 225 | 54,133.71 | 159.65 | -0.29% |
| NZX 50 Index | 13,485.84 | 18.55 | 0.14% |
| S&P 500 | 6,882.72 | 35.09 | -0.51% |
| S&P/ASX 200 | 8,903.60 | 0.40 | -0.00% |
| SSE Composite Index | 4,102.20 | 34.46 | 0.85% |